Supplementary Tables 1-14 from Differential Sensitivity Analysis for Resistant Malignancies (DISARM) Identifies Common Candidate Therapies across Platinum-Resistant Cancers

Supplementary Table S1: Shared mRNA biomarkers predicting PI3K inhibitor sensitivity in SCLC; Supplementary Table S2: Shared protein biomarkers predicting PI3K inhibitor sensitivity in SCLC; Supplementary Table S3: Shared mRNA biomarkers predicting AURKA inhibitor sensitivity in SCLC; Supplementary Table S4: Shared protein biomarkers predicting AURKA inhibitor sensitivity in SCLC; Supplementary Table S5: Shared mRNA biomarkers predicting obatoclax sensitivity in LUAD and SCLC; Supplementary Table S6: DISARM-selected candidates from GDSC for cisplatin-resistant BLCA; Supplementary Table S7: DISARM-selected candidates from GDSC for cisplatin-resistant COAD; Supplementary Table S8: DISARM-selected candidates from GDSC for cisplatin-resistant ESCA; Supplementary Table S9: DISARM-selected candidates from GDSC for cisplatin-resistant HNSC; Supplementary Table S10: DISARM-selected candidates from GDSC for cisplatin-resistant LUAD; Supplementary Table S11: DISARM-selected candidates from GDSC for cisplatin-resistant OV; Supplementary Table S12: DISARM-selected candidates from GDSC for cisplatin-resistant PAAD; Supplementary Table S13: DISARM-selected candidates from GDSC for cisplatin-resistant SCLC; Supplementary Table S14: DISARM-selected candidates from GDSC for cisplatin-resistant STAD.